| Similar Articles |
|---|
 |
The Motley Fool
May 20, 2009
Brian Orelli |
Clinical Trial Positive, Stock Not So Much Isis and Genzyme hit a homer with their cholesterol drug, mipomersen, but they'll need another big play to win the game.   |
The Motley Fool
August 5, 2010
Brian Orelli |
Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still. |
The Motley Fool
February 11, 2010
Brian Orelli |
A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects. |
The Motley Fool
November 18, 2009
Brian Orelli |
Drug Lowers Cholesterol; Stock Follows ISIS has a hard time at American Heart Association despite good efficacy data. |
The Motley Fool
March 31, 2010
Brian Orelli |
A Double-Digit Jump? For That? Isis' drug discovery license doesn't look too exciting to me. |
The Motley Fool
October 4, 2007
Billy Fisher |
Isis Keeps Cholesterol Down, Stock Prices Up Isis Pharmaceuticals reports positive phase 2 results for a cholesterol treatment. The company continues to show progress with its impressive pipeline of 17 other development-stage drugs. Investors, take note. |
The Motley Fool
January 11, 2011
Brian Orelli |
A Clear Drug-Development Path -- Times 2 The FDA throws a fork in the road for Isis and Genzyme. |
The Motley Fool
September 24, 2010
Brian Orelli |
Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year. |
The Motley Fool
January 9, 2008
Brian Orelli |
Genzyme Buys Into Antisense RNA -- Big Time Genzyme buys a piece of Isis' mipomersen at a wowser of a price. |
The Motley Fool
May 17, 2011
Brian Orelli |
$3 Million Here, $1.5 Billion There Isis makes progress in its pact with GlaxoSmithKline. |
BusinessWeek
November 27, 2006
Gene G. Marcial |
ISIS Takes Heart From A Promising Drug ISIS Pharmaceuticals is a name to watch in the lucrative arena of cholesterol reduction. |
The Motley Fool
April 9, 2008
Brian Orelli |
Isis Ignited by Bristol-Myers Bristol-Myers Squibb selects an Isis-developed compound, triggering a milestone payment. |
The Motley Fool
February 4, 2008
Brian Lawler |
Genzyme Tells It Like It Is Genzyme shows some sparkle at investors' conference. Investors, take note. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
September 14, 2007
Brian Orelli |
J&J's Expensive RNA Purchase Johnson & Johnson sets up a collaboration with Isis Pharmaceuticals to develop compounds to treat diabetes. Investors take note. |
The Motley Fool
April 28, 2008
Brian Orelli |
FDA Moves Isis' Finish Line The FDA tells drugmaker Isis it must complete cancer tests before submitting its marketing application. |
The Motley Fool
January 6, 2004
David Nierengarten |
Isis' 2G Drug Shines Will Isis start making cents from anti-sense drugs? |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
June 23, 2010
Brian Orelli |
A Novel Drug Technology Worth Watching Regulus signs up another microRNA partner. |
BusinessWeek
November 24, 2010
Tom Randall |
Merck May Have a Cholesterol Winner Merck told doctors at the American Heart Assn. annual meeting that new data showed its drug anacetrapib had reduced bad cholesterol by 40 percent while raising good cholesterol by an unprecedented 138 percent. |
The Motley Fool
February 17, 2004
David Nierengarten |
Antisense Making Sense? An update on Genasense, its future, and how the antisense marketplace is shaping up. The FDA has agreed to review the new drug applications. |
The Motley Fool
May 25, 2005
Brian Gorman |
Another Deal for Isis Investors shouldn't get their hopes up over the drugmaker's latest collaboration. |
The Motley Fool
September 20, 2007
Brian Orelli |
A Pharma Divorce, and Good Riddance Merck and Alnylam call it quits. The only real question is why the two didn't end the partnership months ago. What will it mean to investors? |
The Motley Fool
November 22, 2011
Luke Timmerman |
Pfizer Acquires Excaliard, an Isis Spinout With Drug to Fight Excessive Scarring Pfizer is making a new bet on a new drug to fight excessive scarring. |
The Motley Fool
November 15, 2011
Brian Orelli |
Good Data, Big Drug Market, but Still Risky Eli Lilly's evacetrapib is behind Roche and Merck. |
The Motley Fool
December 18, 2008
Brian Orelli |
A Diagnostic Tongue Twister Back-scratch fever between Abbott and Isis. |
The Motley Fool
November 15, 2007
Brian Orelli |
Slowing the Cash Burn Bloody Nose Nastech plans to cut costs following Proctor& Gamble's drop of their osteoporosis drug. Investors, take note. |
The Motley Fool
February 9, 2006
Jason Mac Gurn |
RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals... |
The Motley Fool
May 22, 2008
Brian Orelli |
Merck Can't Achieve Anything The pharmaceutical cancels a troubled clinical trial. |
HHMI Bulletin
May 2011
Sarah C. P. Williams |
The Next Statin Although clinicians have firmly established the link between cholesterol levels and heart disease, there are still more questions than answers when it comes to the nitty-gritty molecular details of this connection. |
The Motley Fool
November 8, 2011
Anders Bylund |
Isis Pharmaceuticals' Shares Plunged: What You Need to Know Shares of drug developer Isis Pharmaceuticals hardly looked like a model of fertility today as they fell 10.5% in heavy intraday trading. |
The Motley Fool
July 8, 2008
Brian Orelli |
Not Teva's Forte Teva Pharmaceutical's Copaxone for multiple sclerosis fails to show a benefit at double strength. Investors take note. |
The Motley Fool
January 5, 2011
Brian Orelli |
Pfizer Goes Back for Seconds Headed back for more from Santaris. The company is putting up just $14 million for expanded access to Santaris' LNA technology. |
The Motley Fool
June 22, 2010
Luke Timmerman |
Regulus Therapeutics Forms $750M MicroRNA Deal With Sanofi The company has found its second big ally from Big Pharma. |
The Motley Fool
December 4, 2008
Brian Orelli |
Poor Pozen It's not often that you see a drug developer release data from two positive phase 3 trials for its lead pipeline compound and see its shares fall more than 4%, but that's what happened to Pozen. |
The Motley Fool
June 23, 2008
Brian Orelli |
FDA Sets a Higher Standard for Merck Merck finally comes clean on what the FDA wants before the drug formally known as Cordaptive (MK-0524A) can be approved. From the looks of it, it's going to be a long wait for Merck. |
The Motley Fool
January 9, 2009
Brian Orelli |
Thanks for Nothing, FDA The Food and Drug Administration says there's still enough evidence that Merck and Schering-Plough's Vytorin works to warrant keeping patients on the drug. |
The Motley Fool
April 21, 2009
Brian Orelli |
Reworking the Broken R&D Model When it comes to drug development, it's becoming increasingly clear that competition isn't always the best thing for the industry. Collaborations will help bring drugs to the market more cheaply. |
Bio-IT World
May 2006 |
News Blast Aids Action... Oxford Universal... Myriad Options... |
InternetNews
November 16, 2010 |
Leading Carriers Team for Mobile Commerce New joint venture, dubbed Isis, sees AT&T, Verizon and T-Mobile partner in an ambitious mobile commerce platform that looks to finally deliver on the promise of the mobile wallet. |
Nutra Solutions
July 1, 2005 |
Lowered LDL Study finds that subjects with moderately high cholesterol experienced a 6% drop in total cholesterol after taking a 5g daily dose of an immunoglobulin protein isolate over a period of three weeks. |
American Family Physician
April 15, 2003 |
Cholesterol What is cholesterol?... Why is a high cholesterol level unhealthy?... When should I start having my cholesterol level checked?... Are there different kinds of cholesterol?... What can I do to improve my cholesterol level?... etc. |
The Motley Fool
October 23, 2008
Brian Orelli |
Glaxo to Competitors: You're Cheaper Than We Are This big pharma has cash and it plans to use it. |
The Motley Fool
February 1, 2008
Brian Lawler |
Credit Crisis Bites Big Pharma Bristol-Myers Squibb takes a $275 million writedown in its investment portfolio for the quarter. |
Chemistry World
June 26, 2009
James Mitchell Crow |
STFC cuts funds to key facilities Key UK national science facilities, including the Diamond Light Source and the ISIS neutron beam laboratory, have had their funding cut.C |
